A Study to Characterize the Clinical Course of Pregnant Women and Children at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn

Erythroblastosis, Fetal Clinical Trial

Official title: A Multicenter, Prospective Observational Study to Characterize the Clinical Course of Pregnant Women and Children at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn

Status Completed

Clinical Trial Summary

The primary purpose of the study is to characterize the current standard of care, clinical course, and outcomes of pregnant women and their offspring at high risk for early onset severe hemolytic disease of the fetus and newborn (EOS-HDFN).

Clinical Trial Description

The outcomes of interest will be assessed from the information collected on the standard of care treatment for EOS-HDFN in pregnant women and their offspring from current pregnancy. ;

Related Conditions & MeSH terms

• Disease Progression
• Early Onset Severe Hemolytic Disease of the Fetus and Newborn (EOS-HDFN)
• Erythroblastosis, Fetal
• Hemolysis

• NCT number: NCT03755128
• Study type: Observational
• Source: Janssen Research & Development, LLC
• Status: Completed
• Start date: January 16, 2019
• Completion date: September 22, 2023